Business
Notice of Investor Presentation
SkinBioTherapeutics plc has announced a presentation for shareholders scheduled for 9am BST on Monday, June 29, 2026, which will be led by the Acting Chair and Interim CEO. This presentation is accessible to all current and prospective shareholders, with the opportunity to submit questions in advance via the Investor Meet Company dashboard until 9am BST on June 28, 2026, or during the live event. Investors can register for free on the Investor Meet Company platform to receive an invitation. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company" or the "Group") Notice of IMC presentation 23 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life sciences business focused on skin health, will be presenting to shareholders at 9am BST on Monday 29 June 2026. The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 28 Jun 2026, 9am BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics via the link HERE . Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited. -Ends- For more information please contact: SkinBioTherapeutics plc Alyson Levett, Acting Chair Rachel Parsonage, Interim CEO [email protected] Singer Capital Markets (Nominated Adviser & Broker) Alex Bond Sara Hale Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting Melanie Toyne-Sewell, Rozi Morris +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix ® , is based upon discoveries made by the translational dermatology team at the University of Manchester. The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain. SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com .
View stock analysis, news, and events for Skinbiotherapeutics Plc